Initial Oncologic Prices Must Factor In Future Changes In Dosing – Bristol
Executive Summary
Manufacturers should take into account potential differences in dosing for future indications when setting prices for novel oncologics, Bristol-Myers Squibb CFO Andrew Bonfield said June 15
You may also be interested in...
Safety May Decide Sprycel/Tesigna Battle For Gleevec Failures, Novartis Says
Novartis' investigational chronic myeloid leukemia therapy Tasigna (nilotinib) appears to not have the risk of pleural effusions seen with Bristol-Myers Squibb's Sprycel (dasatinib), Novartis Senior VP-Head of Development Alessandro Riva said June 5
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Up-front spending on pharmaceuticals to treat colorectal cancer in the U.S. would be $7.5 bil. per year if oncologists use newly launched therapies without restrictions, Memorial-Sloan Kettering Cancer Center researcher Leonard Saltz, MD, told the American Society of Clinical Oncology annual meeting June 5 in New Orleans
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011